

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Coalition For Affordable Drugs XI LLC,
Petitioner

v.

Insys Pharma, Inc.,
Patent Owner

U.S. Patent 8,486,972

PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO.
8,486,972 AND
MANDATORY NOTICES UNDER 37 C.F.R. § 42.8

Mailed August 24, 2015

TABLE OF CONTENTS

<u>NOTICE OF RELATED MATTERS</u>	3
<u>NOTICE OF SERVICE INFORMATION</u>	3
<u>GROUND FOR STANDING</u>	3
<u>STATEMENT OF PRECISE RELIEF REQUESTED</u>	3
<u>STATEMENT OF REASONS FOR RELIEF REQUESTED</u>	6
II. <u>THE CLAIMS UNDER CONSIDERATION</u>	8
III. THE '972 PATENT AND PROSECUTION HISTORY OF THE '972 PATENT	9
IV. <u>CLAIM CONSTRUCTION</u>	23
A. “MEAN TIME TO MAXIMUM PLASMA CONCENTRATION (T _{MAX}) OF FENTANYL OF FROM ABOUT 5 TO ABOUT 120 MINUTES”	23
B. “DISCRETE LIQUID DROPLETS”	25
V. <u>LEVEL OF SKILL IN THE ART</u>	26
VI. <u>CLAIMS 1-3 ARE OBVIOUS</u>	26
<u>A. GROUND 1 -- CLAIMS 1 AND 3 ARE UNPATENTABLE AS OBVIOUS OVER ROSS GB, IN VIEW OF ROSS US2006, AND THE '862 PATENT</u>	27
<u>1. INDEPENDENT CLAIM 1</u>	27
A. <i>UNIT DOSE</i>	28
B. <i>NON-PROPELLANT</i>	28
C. <i>SUBLINGUAL FENTANYL FORMULATION COMPRISING DISCRETE LIQUID DROPLETS</i>	28
D. <i>AN EFFECTIVE AMOUNT OF FENTANYL</i>	29
E. <i>A PHARMACEUTICALLY ACCEPTABLE LIQUID CARRIER</i>	29
F. <i>WHEREIN THE SUBLINGUAL FENTANYL FORMULATION COMPRISES: FROM ABOUT 0.1% TO ABOUT 0.8% BY WEIGHT OF FENTANYL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF</i>	30
G. <i>THE SUBLINGUAL FENTANYL FORMULATION COMPRISES ... FROM ABOUT 20% TO ABOUT 60% BY WEIGHT OF ETHANOL</i>	31

H. THE SUBLINGUAL FENTANYL FORMULATION COMPRISES ... FROM ABOUT 4% TO ABOUT 6% BY WEIGHT OF PROPYLENE GLYCOL31

I. SUBLINGUAL ADMINISTRATION TO A HUMAN.....34

J. SAID SUBLINGUAL FENTANYL FORMULATION PROVIDES A MEAN TIME TO MAXIMUM PLASMA CONCENTRATION (T_{MAX}) OF FENTANYL OF FROM ABOUT 5 TO ABOUT 120 MINUTES.....34

3. DEPENDENT CLAIM 3.....37

A. AFTER SUBLINGUAL ADMINISTRATION TO A HUMAN, THE SUBLINGUAL FENTANYL FORMULATION PROVIDES A MEAN TIME TO MAXIMUM PLASMA CONCENTRATION (T_{MAX}) OF FENTANYL OF FROM ABOUT 10 TO ABOUT 60 MINUTES.38

B. GROUND 2 -- CLAIM 2 IS UNPATENTABLE AS OBVIOUS OVER ROSS GB, IN VIEW OF ROSS US2006, THE '862 PATENT, AND THE '496 PUBLICATION.....40

1. DEPENDENT CLAIM 2.....40

2. THE PRIOR ART AND ITS COMPARISON TO CLAIM 240

A. SAID DISCRETE LIQUID DROPLETS HAVE A SIZE DISTRIBUTION OF FROM ABOUT 10 μM TO ABOUT 200 μM.41

C. THE PATENT OWNER'S ARGUMENT FOR SECONDARY CONSIDERATIONS SET FORTH IN THE PROSECUTION FILE HISTORY ARE MISLEADING AND WRONG43

1. PATENT OWNER'S ARGUMENT FOR SECONDARY CONSIDERATIONS IS NOT COMMENSURATE WITH THE SCOPE OF THE CLAIMS44

2. A FAST ONSET OF FIVE MINUTES WAS NOT UNEXPECTED BECAUSE A COMMERCIAL FENTANYL NASAL SPRAY ACHIEVED A FIVE MINUTES ONSET EFFECT47

3. A FAST ONSET OF FIVE MINUTES WAS NOT UNEXPECTED BECAUSE OTHER PRIOR ART REFERENCES REPORTED EFFICACIOUS PAIN RELIEF AT FIVE MINUTES OR LESS50

4. A PRIOR ART FENTANYL NASAL SPRAY ACHIEVED A BLOOD CONCENTRATION FIVE MINUTES POST ADMINISTRATION THAT WAS HIGHER THAN THE CONCENTRATION OF THE CLAIMED INVENTION WITH THE SAME DOSAGE53

VII. CONCLUSION55

TABLE OF AUTHORITIES

CASES

KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 418 (2007) 26, 27
In re Cuozzo Speed Techs., LLC, No. 2014-1301, 2015 U.S. App. LEXIS 1699,
Slip. Op. at 21 (Fed. Cir. Feb. 4, 2015). 23
Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 1369 (Fed. Cir. 2012),
cert denied, 133 S. Ct. 1736 (2013)). 27

RULES

37 C.F.R. § 42.8(b)(1)..... 1
37 C.F.R. § 42.100(b) 23

Coalition For Affordable Drugs XI LLC ("CFAD" or "Petitioner") requests *inter partes* review of claims 1 - 3 of U.S. Patent No. 8,486,972 ("the '972 Patent") (Exhibit 1001) assigned to Insys Pharma, Inc. ("Insys").

NOTICE OF LEAD AND BACKUP COUNSEL

Lead Counsel:	Backup Counsel:
Dr. Gregory J. Gonsalves Reg. No. 43,639 2216 Beacon Lane Falls Church, VA 22043 (571) 419-7252 gonsalves@gonsalveslawfirm.com	Christopher Casieri McNeely, Hare & War LLP 12 Roszel Road, Suite C104 Princeton, NJ 08540 Phone: 609 731 3668 chris@miplaw.com

NOTICE OF EACH REAL-PARTY-IN-INTEREST

Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies that Coalition For Affordable Drugs XI LLC ("CFAD"), Hayman Credes Master Fund, L.P. ("Credes"), Hayman Orange Fund SPC – Portfolio A ("HOF"), Hayman Capital Master Fund, L.P. ("HCMF"), Hayman Capital Management, L.P. ("HCM"), Hayman Offshore Management, Inc. ("HOM"), Hayman Investments, L.L.C. ("HI"), nXn Partners, LLC ("nXnP"), IP Navigation Group, LLC ("IPNav"), J Kyle Bass, and Erich Spangenberg are the real parties in interest (collectively, "RPI").

The RPI hereby certify the following information: CFAD is a wholly owned

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.